HTG Molecular Diagnostics, Inc. (HTGM)
| Market Cap | 39.02M |
| Revenue (ttm) | 7.76M |
| Net Income (ttm) | -20.26M |
| Shares Out | 6.04M |
| EPS (ttm) | -4.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 26 |
| Last Price | $6.04 |
| Previous Close | $5.37 |
| Change ($) | 0.67 |
| Change (%) | 12.48% |
| Day's Open | 5.80 |
| Day's Range | 5.75 - 6.38 |
| Day's Volume | 165,962 |
| 52-Week Range | 3.50 - 11.25 |
TUCSON, Ariz., July 23, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that, on Jul...
HTG Molecular Diagnostics Inc (NASDAQ: HTGM) has received the first commercial orders for its planned HTG Transcriptome Panel and has signed agreements with its first two Early Adopter Program (EAP) col...
TUCSON, Ariz., May 24, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that its HTG ...
Call scheduled for today, May 13, at 4:30 pm ET Call scheduled for today, May 13, at 4:30 pm ET
TUCSON, Ariz., May 04, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will report...
TUCSON, Ariz., April 05, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today reported certain prel...
Call scheduled for today, March 25, at 4:30pm ET Call scheduled for today, March 25, at 4:30pm ET
HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
TUCSON, Ariz., March 16, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will repo...
Roche Holding AG (OTC: RHHBY) acquired GenMark Diagnostics, Inc (NASDAQ: GNMK) in a $1.8 billion deal on Monday, the same day Veracyte Inc (NASDAQ: VCYT) announced it completed the acquisition of Deciph...
TUCSON, Ariz., Feb. 26, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has compl...
Timothy Johnson to Retire from the Board; Ann Hanham, Ph.D. Remains Lead Independent Director Timothy Johnson to Retire from the Board; Ann Hanham, Ph.D. Remains Lead Independent Director
TUCSON, Ariz., Dec. 30, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has ...
HTG Announces First Collaborator in Early Access Program for its Prototype Whole Transcriptome Panel
TUCSON, Ariz., Dec. 18, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has ...
TUCSON, Ariz., Dec. 08, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has ...
TUCSON, Ariz., Nov. 23, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that as a result o...
HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q3 2020 Results - Earnings Call Transcript
Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) decreased 3.2% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share rose 53.33% year over year to ($0.07)...
Call scheduled for today, November 10, at 4:30pm ET Call scheduled for today, November 10, at 4:30pm ET
TUCSON, Ariz., Nov. 02, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the completi...
TUCSON, Ariz., Oct. 30, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a life science company whose mission is to advance precision medicine, today announced that it will repor...
TUCSON, Ariz., Sept. 08, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced John Lubniewski, ...
TUCSON, Ariz., Aug. 18, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the commer...
TUCSON, Ariz., Aug. 14, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today provided an update r...
HTG Molecular Diagnostics' (HTGM) CEO John Lubniewski on Q2 2020 Results - Earnings Call Transcript
Shares of HTG Molecular Diagnostics (NASDAQ:HTGM) were flat in after-market trading after the company reported Q2 results.
HTG Molecular Diagnostics, Inc. (HTGM) delivered earnings and revenue surprises of 0.00% and 3.32%, respectively, for the quarter ended June 2020.
Call scheduled for today, August 11, at 4:30pm ET Call scheduled for today, August 11, at 4:30pm ET
TUCSON, Ariz., Aug. 10, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the signin...
On Tuesday, August 11, HTG Molecular Diagnostics (NASDAQ: HTGM) will report its last quarter's earnings.
TUCSON, Ariz., Aug. 05, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM), a diagnostic company whose mission is to advance precision medicine, today announced that it will repor...
TUCSON, Ariz., Aug. 04, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the pre-la...
Entire HTG RUO profiling assay menu now available for use on both Illumina’s and Thermo Fisher Scientific’s NGS platform Entire HTG RUO profiling assay menu now available for use on both Illumina’s and ...
TUCSON, Ariz., July 28, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the launch...
HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
Researchers at University of Pennsylvania Perelman School of Medicine and Charité University Hospitals, Berlin recognized for cutting edge work in autoimmune diseases Researchers at University of Pennsy...
TUCSON, Ariz., June 25, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it ha...
TUCSON, Ariz., June 23, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced its HTG Ed...
Comprehensive Panel Designed to Provide Molecular Characterization of Aggressive Lymphomas Comprehensive Panel Designed to Provide Molecular Characterization of Aggressive Lymphomas
TUCSON, Ariz., June 11, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the signin...
Top Ranked Momentum Stocks to Buy for May 14th
HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q1 2020 Results - Earnings Call Transcript
HTG Molecular Diagnostics Inc (HTGM) delivered earnings and revenue surprises of 0.00% and -2.41%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the st...
Call scheduled for today, May 13, at 4:30pm ET Call scheduled for today, May 13, at 4:30pm ET
HTG Molecular Diagnostics Inc (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HTG Molecular Diagnostics, Inc. (HTGM) CEO John Lubniewski on Q4 2019 Results - Earnings Call Transcript
HTG Molecular Diagnostics, Inc. (HTGM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.
TUCSON, Ariz., Feb. 11, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today highlighted the HTG ...
TUCSON, Ariz., Feb. 05, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today highlighted the repr...
TUCSON, Ariz., Jan. 28, 2020 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced it has rec...
About HTGM
HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq D... [Read more...]
| Industry Diagnostics & Research | IPO Date May 6, 2015 |
| CEO John Lubniewski | Employees 83 |
| Stock Exchange NASDAQ | Ticker Symbol HTGM |
Financial Performance
In 2020, HTGM's revenue was $8.55 million, a decrease of -55.48% compared to the previous year's $19.20 million. Losses were -$20.87 million, 8.15% more than in 2019.
Analyst Forecasts
According to 4 analysts, the average rating for HTGM stock is "Buy." The 12-month stock price forecast is 9.75, which is an increase of 61.42% from the latest price.